Novo Nordisk has agreed to buy Akero Therapeutics and its drug candidate for metabolic dysfunction-associated steatohepatitis (MASH) for $4.7 billion upfront, shortly after claiming FDA approval to ...

Novo Nordisk has reduced the price of its two semaglutide-based therapies – Ozempic for diabetes and Wegovy for obesity – to a price of $499 for those paying for the drugs out of pocket. The price cut ...

Pfizer Inc said on Monday it has filed a second lawsuit against Metsera and its controlling shareholders, as well as Novo Nordisk in a Delaware federal court, accusing them of anticompetitive conduct.

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.